Lilly's Taltz meets in Phase III for genital psoriasis

In September, Eli Lilly and Co. (NYSE:LLY) reported data from a Phase III trial in 149 patients with moderate to severe genital psoriasis showing that subcutaneous Taltz ixekizumab (LY2439821) met the primary endpoint of a greater proportion of patients with

Read the full 404 word article

User Sign In